We are proud to announce that our client EmstoPA has received the Regulatory Endorsement of Development Program by British MHRA and US FDA: The Medicines & Healthcare Products Regulatory Agency have recently reviewed and endorsed EmstoPA’s Plan, providing excellent feedback on each aspect. FDA has also reviewed and provided positive feedback for EmstoPA development plan
EmstoPA has developed a novel tPA-neutralising antidote
The availability of an antidote to address possible severe hemorrhage caused by tPA, has the potential to save lives and reduce disability in multiple patients worldwide.
tPA is a life-saving drug but can cause severe bleeding, often into the brain, which is difficult to control. As a result, it has limited usage.
EmstoPA is an emergency treatment, stops the bleeding and saves lives as well as reduces disability.